Elder Pharmaceuticals and Enzymotec to Sell CardiaBeat in India
Elder Pharmaceuticals Ltd, based in Mumbai, is one of the fastest growing pharmaceuticals companies and is a segment leader in the therapeutic categories of women health care, nutraceuticals, and wound care.
21/03/07 The Indian Pharmaceuticals company Elder and the Israeli biotech company Enzymotec have announced on signing an agreement for launching CardiaBeat in the Indian market.
CardiaBeat is a conjugated matrix of sterol-omega-3, which exhibits multiple actions for CVD risk reduction in a compact form. It was shown in a clinical trial to reduce LDL levels similarly to plant sterols, while having a greater TG reduction effect in comparison to fish oil, without adversity affecting vitamin absorption.
Elder Pharmaceuticals Ltd, based in Mumbai, is one of the fastest growing pharmaceuticals companies and is a segment leader in the therapeutic categories of women health care, nutraceuticals, and wound care. “We are confident that our expertise in handling innovative products, as well as our extensive distribution network covering the entire country, will be the key success factors for CardiaBeat in India”.
Says Mr. Alok Saxena, Director, Elder Pharmaceuticals, "India is a strategic market for us. The increase in the occurrence of obesity, heart disease, hypertension, and diabetes as well as consumers seeking for innovative self – medicate products, are all important indicators favoring launch of innovative products in India. "We expect that the agreement between Elder and Enzymotec will further establish both companies' leading position in the Indian nutraceutical market," says Dr. Ariel Katz, Enzymotec’s CEO.
